The markets closed mixed with the Dow adding 15 points to 12,965 over concerns that the Greek economy will remain in a prolonged recession. Nasdaq slipped 3 points to 2948.
On the upside
Shareholders approved the merger of Eldorado Gold (NYSE: EGO) with European Goldfields.
Shares of Polypore International (NYSE: PPO) advanced ahead of its earnings release tomorrow.
On the downside
The Food and Drug Administration suspended drug trials of GTx's (Nasdaq: GTXI) prostate cancer treatment Capesaris due to an increased risk of bloom clots.
FDATracker.com expects the Food and Drug Administration to reject Vivus' (Nasdaq: VVUS) obesity treatment Qnexa.
Boyd Gaming (NYSE: BYD) narrowed fourth quarter losses but the results fell short of analyst expectations.
In the broad market, declining issues outpaced advancers by a slim margin on the NYSE and by more than 5 to 3 on Nasdaq. The Russell 2000 which tracks small cap stocks lost 5 points to 823.